Indeed, the methylation status of the BIM promoter, is associated with an unfavorable prognosis in CML diagnosed patients [104], while an increased BCR promoter methylation correlates with a more favorable response to Imatinib [105]. The gene discussed is BCL2L11; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.